Clodronate liposome administration either abrogated the benefit of CD40 agonist in the KPC genetically engineered mouse model (56) or promoted antitumor activity of CD40 agonist + gemcitabine in a subcutaneous PDA model in wild-type mice (72). The gene discussed is CD40; the disease is Patent ductus arteriosus.